Record overview
Status and phase
Status: TERMINATED
Phase: PHASE2
Sponsor: GlaxoSmithKline
Condition: Melanoma
NCT02314143
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.